NCT02624947: A trial that was reported late by Novavax
This trial has reported, although it was 211 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02624947 |
|---|---|
| Title | A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 31, 2015 |
| Completion date | Dec. 28, 2018 |
| Required reporting date | Dec. 28, 2021, midnight |
| Actual reporting date | July 27, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 211 |